Publication:
Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2

dc.contributor.authorWeecharangsan W.
dc.contributor.authorLee R.J.
dc.date.accessioned2021-04-05T03:34:01Z
dc.date.available2021-04-05T03:34:01Z
dc.date.issued2012
dc.date.issuedBE2555
dc.description.abstractPrevious study has shown human serum albumin (HSA) coated liposomes can deliver bcl-2 antisense oligodeoxyribonucleotide (ODN) into KB carcinoma cells, and decrease bcl-2 mRNA and protein expression level. In the current study, cell growth inhibition and chemosensitization of KB cells were evaluated. Liposomes composed of dimethyldioctadecyl ammonium bromide/egg phosphatidylcholine/ α-tocopheryl polyethylene glycol 1000 succinate (58:40:2 molar ratio) complexed with bcl-2 antisense ODN and coated with HSA were examined for cell growth inhibition and sensitization to a commonly used chemotherapeutic drug, doxorubicin. HSA-coated liposomeODN complexes effectively inhibited cell growth in the range of ODN concentration of 0.457.2 M. Upon posttreatment with doxorubicin, the cytotoxicity was further significantly increased compared to the ODN complexes alone. The cytotoxicity was dependent on antisense ODN concentration, incubation time and doxorubicin concentration, and relatively independent on HSA concentration. This study suggests that HSA-coated liposomes are effective delivery vehicles for antisense ODN with potential therapeutic application and can be effectively combined with doxorubicin. © 2012 Informa Healthcare USA, Inc.
dc.format.mimetypeapplication/pdf
dc.identifier.citationDrug Delivery. Vol 19, No.6 (2012), p.292-297
dc.identifier.doi10.3109/10717544.2012.714810
dc.identifier.issn10717544
dc.identifier.other2-s2.0-84866256041
dc.identifier.urihttps://hdl.handle.net/20.500.14740/6989
dc.rights.holderมหาวิทยาลัยศรีนครินทรวิโรฒ
dc.subject.otherAlpha tocopheryl polyethylene glycol 1000 succinate
dc.subject.otherAntisense oligodeoxynucleotide
dc.subject.otherDimethyldioctadecyl ammonium bromide
dc.subject.otherDoxorubicin
dc.subject.otherEgg phosphatidylcholine
dc.subject.otherHuman serum albumin
dc.subject.otherLiposome
dc.subject.otherMessenger RNA
dc.subject.otherProtein bcl 2
dc.subject.otherUnclassified drug
dc.subject.otherArticle
dc.subject.otherCarcinoma cell
dc.subject.otherCell growth
dc.subject.otherCell strain KB
dc.subject.otherChemosensitization
dc.subject.otherConcentration response
dc.subject.otherControlled study
dc.subject.otherCytotoxicity
dc.subject.otherDrug coating
dc.subject.otherDrug delivery system
dc.subject.otherGenetic transfection
dc.subject.otherGrowth inhibition
dc.subject.otherHuman
dc.subject.otherHuman cell
dc.subject.otherIncubation time
dc.subject.otherMouth carcinoma
dc.subject.otherPriority journal
dc.subject.otherProtein expression
dc.subject.otherAntibiotics, Antineoplastic
dc.subject.otherCell Growth Processes
dc.subject.otherCell Line, Tumor
dc.subject.otherDose-Response Relationship, Drug
dc.subject.otherDoxorubicin
dc.subject.otherGene Expression Regulation, Neoplastic
dc.subject.otherHumans
dc.subject.otherKB Cells
dc.subject.otherLipids
dc.subject.otherLiposomes
dc.subject.otherMouth Neoplasms
dc.subject.otherOligodeoxyribonucleotides, Antisense
dc.subject.otherProto-Oncogene Proteins c-bcl-2
dc.subject.otherRNA, Messenger
dc.subject.otherSerum Albumin
dc.subject.otherTime Factors
dc.titleGrowth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84866256041&doi=10.3109%2f10717544.2012.714810&partnerID=40&md5=49c52723b72986b90604e875f73414ff

Files